HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Monday 27 July 2015

NICE triennial review

14 recommendations, with the most important (to us) being:

Recommendation 1: That the functions of NICE continue.

Recommendation 4: The health and care system is operating in a time of
unprecedented financial constraints and NICE should play an integral role in
supporting it to achieve its objectives and make best use of resources. It should do
this by:
  • Working with the Department and NHS England to develop and publish a set of key performance indicators that reflect strategic objectives and assess the impact of the organisation, which are supported by appropriate input, output, or other performance targets [in 2015/16].
  • Working with other health and care leaders; especially NHS England, Public Health England and Care Quality Commission (CQC), to align the approach to implementation of NICE guidance and recommendations in order to support organisations in implementation activity [by the end of 2015].
Recommendation 5: DH should consider the clinical and cost effectiveness
appraisals currently conducted within the health and care system, including (but
not limited to) the Cancer Drugs Fund (CDF) and the Joint Commission on
Vaccinations and Immunisation (JCVI), with a view to establishing whether NICE
should be the single expert body with responsibility for such appraisals [by April
2016].

Recommendation 6: Following the findings of the Accelerated Access Review,
the Department of Health and NICE, with input from NHS England, should
consider what changes to NICE’s methods and processes are necessary to
enable the health and care system make best use of the resources available [by
July 2016].
Posted by at
Labels: